Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

PURPOSE: Following promising responses to the DNA methyltransferase (DNMT) inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) combined with tetrahydrouridine (THU) in phase 1 testing, we initiated a non-randomized phase 2 study to assess response to this combination in patients with advanced solid tumor ty...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Chemother Pharmacol
Главные авторы: Coyne, Geraldine O.’Sullivan, Wang, Lihua, Zlott, Jennifer, Juwara, Lamin, Covey, Joseph M., Beumer, Jan H., Cristea, Mihaela C., Newman, Edward M., Koehler, Stephen, Nieva, Jorge J., Garcia, Agustin A., Gandara, David R., Miller, Brandon, Khin, Sonny, Miller, Sarah B., Steinberg, Seth M., Rubinstein, Larry, Parchment, Ralph E., Kinders, Robert J., Piekarz, Richard L., Kummar, Shivaani, Chen, Alice P., Doroshow, James H.
Формат: Artigo
Язык:Inglês
Опубликовано: Springer Berlin Heidelberg 2020
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7188725/
https://ncbi.nlm.nih.gov/pubmed/32314030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04073-5
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы